Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients;Distribución anormal de la grasa corporal y tipo de tratamiento antirretroviral como predictores de riesgo de enfermedad cardiovascular en pacientes infectados por el virus de la inmunodeficiencia humana

Medicina Clinica

Volumn 122, Issue 19, 2004, Pages 721-726

  Ena, Javier ^a   Benito, Concepción ^a   Llácer, Pau ^a   Pasquau, Francisco ^a   Amador, Concepción ^a  

^a HOSPITAL MARINA BAIXA   (Spain)

Author keywords

Anti retroviral therapy; Cardiovascular diseases; Cross sectional studies; Highly active; HIV associated lipodystrophy syndrome; Hyperlipidemia

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3142664217     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13062189     Document Type: Article

References (22)

1. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-62.
2. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6.
3. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
4. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
5. Rodríguez Vidigal FF, Muñoz Sanz A. Alteraciones del metabolismo de los lípidos en los pacientes infectados por el virus de la inmunodeficiencia humana. Una hipótesis acerca de su patogenia. Med Clin (Barc) 2000;115:145-50.
6. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-98.
7. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallotas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
8. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:1413-46.
9. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002;25(Suppl 1):S5-20.
10. Miró JM, Antela A, Arrizabalaga J, Clotet B, Gatell JM, Guerra L, et al. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretrovírico en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2000 (I). Enferm Infecc Microbiol Clin 2000;18:329-51.
11. Carr A, Samaras K, Thodsdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
12. Braunwald E. Ustable angina. A classification. Circulation 1989;80:410-4.
13. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arvelier D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
15. Hadigan C, Meigs JB, Corcoran C, Riestschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-9.
16. Estrada V, Serrano-Rios M, Martínez-Larrad MT, Villar NG, González-López A, Téllez MJ, et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:32-40.
17. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave J-P, et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 2001;15:329-34.
18. Barthelemy O, Escaut L, Vayre F, Gallet B, Pulik M, Heloire F, et al. Acute coronary syndromes in patients treated with HIV protease inhibitors. Presse Med 2002;31:343-8.
19. Dronda F, Moreno S, Pérez-Eliás MJ, Casado JL, Antela A, Moreno A. Vascular disease in HIV-infected patients: a comparative study of two different therapeutic periods (1994-1997 versus 1998-2000). AIDS 2002;16:1971-3.
20. Carr A, Workman C, Smith, Hoy J, Hudson J, Doong N, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. A randomized trial. JAMA 2002;288:207-15.
21. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
22. Dubé MP, Sprecher D, Henry WK, Aberg JA, Tomani FJ, Hodis HN, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-24.